Binding of vinblastine and estramustine to isolated plasma membrane fractions from human prostate and prostatic tumors.
The binding of vinblastine (VLB) and estramustine (EM) to plasma membranes isolated from human prostate, prostatic tumors as well as from Dunning rat prostatic AT-1 tumors was studied. In addition, the uptake of these drugs in AT-1 tumor cells in culture was examined. Binding of VLB was six-fold lower than that of EM in membrane preparations from all three sources. The uptake of VLB in the intact AT-1 cells was nearly five-fold lower than that of EM. At concentrations comparable to those achieved clinically the binding of EM was 100-fold higher than that of VLB. The data suggest that, owing to a very high membrane concentration of EM relative to that of VLB, the active efflux VLB in drug resistant cells would be impeded. This in turn would lead to a higher accumulation of VLB in cells that actively transport cytotoxic drugs.
Batra
S
S
Department of Obstetrics and Gynecology, University Hospital Lund, Sweden.
Larsson
I
I
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000378:metabolism*; D000972:Antineoplastic Agents, Phytogenic / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism; D004961:Estramustine / Q000378:metabolism*; D006801:Humans; D008297:Male; D011467:Prostate / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000378:metabolism*; D051381:Rats; D014407:Tumor Cells, Cultured; D014747:Vinblastine / Q000378:metabolism*
D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D004961:Estramustine; D014747:Vinblastine